Recruiting
Phase 3

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT03574571

Conditions

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Docetaxel 75 mg/m2

Docetaxel 60 mg/m2

Radium-223

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information